Ask Edgar App

Ticker: $BIAF Form Type: 8-K Summary: bioAffinity Technologies, Inc. announced that its CyPath® Lung test will be featured at an invitation-only symposium at the Cleveland Clinic on April 16, 2026. This information was released in an earlier press release on April 7, 2026. Link: app.askedgar.io/filing?ticker=…

Ticker: $ARTL Form Type: 8-K Summary: Artelo Biosciences, Inc. has regained compliance with Nasdaq’s minimum stockholders’ equity and annual meeting requirements. The company will be subject to a mandatory panel monitor through April 6, 2027, during which any future failure to meet the equity rule could lead to immediate delisting procedures. This information was released in an earlier press release on April 7, 2026. Link: app.askedgar.io/filing?ticker=…

Ticker: $MGN Form Type: 3 Summary: Phua Zhi Yong has filed a Form 3 to report their initial ownership stake in Megan Holdings Ltd. following their appointment as an insider. The filing indicates that the reporting person currently holds zero shares of the company's stock. Link: app.askedgar.io/filing?ticker=…

Ticker: $SLNO Form Type: SC14D9C Summary: Soleno Therapeutics, Inc. filed this document as a preliminary communication regarding a planned merger with Neurocrine Biosciences, Inc. and its subsidiary, Sigma Merger Sub, Inc., pursuant to an agreement dated April 5, 2026. The filing incorporates information from a Form 8-K filed on April 6, 2026, and includes various communication materials such as employee letters, FAQs, and letters to stakeholders regarding the transaction. Link: app.askedgar.io/filing?ticker=…

Ticker: $MIGI Form Type: 8-K Summary: Mawson Infrastructure Group Inc. entered into a Cooperation Agreement with the Endeavor Parties, which includes provisions to settle litigation and implement non-disparagement agreements through April 2029. As part of this agreement, three directors resigned from the Board, and five new directors—Kyle B. Danges, K. Rodger Davis, Lisa R. Hough, Cody Smith, and Phillip Stanley—were appointed effective April 6, 2026. This information was released in an earlier press release on April 6, 2026. Link: app.askedgar.io/filing?ticker=…

Ticker: $SLNO Form Type: SC TO-C Summary: This filing serves as a preliminary communication regarding a planned tender offer by Neurocrine Biosciences, Inc. to acquire all outstanding shares of Soleno Therapeutics, Inc. The acquisition is being conducted through a wholly owned subsidiary of Neurocrine, Sigma Merger Sub, Inc., pursuant to a merger agreement dated April 5, 2026. This document is for informational purposes only and does not constitute an offer to purchase or a solicitation of an offer to sell securities. Link: app.askedgar.io/filing?ticker=…

Ticker: $OFAL Form Type: 8-K Summary: OFA Group’s subsidiary, Office for Fine Architecture Limited, has entered into an agreement to acquire a 50% co-ownership interest in the QIKBIM intellectual property from Alan To AI Consultancy Co. Limited for a total purchase price of $17,500,000. The company has already paid $11,994,800, with the remaining balance to be settled through final installments and supplemental payments by December 31, 2026. Under the agreement, OFA Group gains sole operational and strategic control over the QIKBIM business, while the seller will provide 24 months of technical transition and maintenance support. Link: app.askedgar.io/filing?ticker=…

Ticker: $STIM Form Type: 8-K Summary: Neuronetics, Inc. announced that former CEO Keith J. Sullivan will provide consulting services through March 31, 2027, and that CFO Steven E. Pfanstiel will resign effective May 1, 2026. The company is initiating a workforce reduction of up to 5% to optimize costs, expecting $0.2 million in restructuring charges and $2.5 million to $3.0 million in annualized savings. Additionally, the company reaffirmed its financial guidance, which was previously released in a press release on April 6, 2026. Link: app.askedgar.io/filing?ticker=…

Ticker: $ZSPC Form Type: 4 Summary: Michael S. Harper, the Chief Product, Engineering and Marketing Officer of zSpace, Inc., reported the vesting of 17,000 restricted stock units (RSUs) into common stock on April 1, 2026. Following this transaction, he holds a total of 68,000 shares of common stock. Additionally, Mr. Harper was granted 136,000 new RSUs, which are scheduled to vest in four equal quarterly installments beginning July 1, 2026. Link: app.askedgar.io/filing?ticker=…

Ticker: $ZSPC Form Type: 4 Summary: Paul Kellenberger, the CEO of zSpace, Inc., reported the vesting of 33,500 Restricted Stock Units (RSUs) into common stock on April 1, 2026. Following this transaction, he holds a total of 402,000 shares of common stock. Additionally, he was granted a new award of 268,000 RSUs, which are scheduled to vest in four equal quarterly installments beginning July 1, 2026. Link: app.askedgar.io/filing?ticker=…

Ticker: $ZSPC Form Type: 4 Summary: Abhay Pande, a reporting person for zSpace, Inc., was granted 13,441 restricted stock units (RSUs) on April 1, 2026. These RSUs will vest in four equal quarterly installments starting on July 1, 2026, provided he remains in continuous service with the company. Following this transaction, he holds 13,441 shares of common stock. Link: app.askedgar.io/filing?ticker=…

Ticker: $ZSPC Form Type: 4 Summary: Jane Swift was granted 13,441 restricted stock units (RSUs) by zSpace, Inc. on April 1, 2026. These units will vest in four equal quarterly installments starting on July 1, 2026, provided she remains in continuous service with the company. Following this transaction, she holds a total of 13,441 shares of common stock. Link: app.askedgar.io/filing?ticker=…

Ticker: $ZSPC Form Type: 4 Summary: Joanna Morris, an insider at zSpace, Inc., was granted 13,441 restricted stock units (RSUs) on April 1, 2026. These RSUs will vest in four equal quarterly installments starting on July 1, 2026, provided she remains in continuous service with the company. Following this transaction, she holds a total of 13,441 shares of common stock. Link: app.askedgar.io/filing?ticker=…

Ticker: $ZSPC Form Type: 4 Summary: Erick DeOliveira, the Chief Financial Officer of zSpace, Inc., reported the vesting of Restricted Stock Units (RSUs) into 17,000 and 4,083 shares of common stock on April 1, 2026. Additionally, he was granted a new award of 136,000 RSUs, which are scheduled to vest in four equal quarterly installments beginning July 1, 2026. Following these transactions, DeOliveira holds a total of 236,667 shares of common stock. Link: app.askedgar.io/filing?ticker=…

Ticker: $BTBD Form Type: 8-K Summary: BT Brands, Inc. has filed the consent of its independent registered public accounting firm regarding the company's consolidated financial statements for the fiscal year ended December 28, 2025. This consent is being incorporated by reference into the company's Registration Statement on Form S-3. Link: app.askedgar.io/filing?ticker=…

Ticker: $DEFT Form Type: 6-K Summary: DeFi Technologies Inc. filed a Form 6-K announcing a shareholder call to discuss its 2025 financial results, which included $99.1 million in revenue and $62.7 million in net income. This information was released in an earlier press release dated April 6, 2026. Link: app.askedgar.io/filing?ticker=…

Ticker: $UGRO Form Type: 8-K Summary: On April 6, 2026, urban-gro, Inc. released an updated investor presentation to be used in meetings with investors and for potential capital-raising activities. The company also issued a press release on April 6, 2026, announcing the availability of this presentation and providing general business updates. Link: app.askedgar.io/filing?ticker=…

Ticker: $SLNO Form Type: 8-K Summary: Soleno Therapeutics, Inc. has entered into a definitive merger agreement to be acquired by Neurocrine Biosciences, Inc. for $53.00 per share in an all-cash tender offer. This information was released in an earlier press release on April 6, 2026. The transaction, which includes support agreements from certain principal stockholders, is expected to close by October 5, 2026, subject to customary closing conditions and regulatory approvals. Link: app.askedgar.io/filing?ticker=…

Ticker: $SLNO Form Type: SC TO-C Summary: Neurocrine Biosciences, Inc. has entered into a definitive merger agreement to acquire all outstanding shares of Soleno Therapeutics, Inc. for $53.00 per share in an all-cash tender offer. Following the completion of the tender offer, Soleno will become a wholly owned subsidiary of Neurocrine. This information was released in an earlier press release on April 6, 2026. Link: app.askedgar.io/filing?ticker=…

Ticker: $ELAB Form Type: 8-K Summary: PMGC Holdings Inc. announced that its newly formed, wholly owned subsidiary, NorthStrive Defense Tech LLC, issued a press release on April 6, 2026. This information was released in an earlier press release on April 6, 2026. Link: app.askedgar.io/filing?ticker=…